Efficacy of istradefylline for gait disorders with freezing of gait in Parkinson’s disease: A single-arm, open-label, prospective, multicenter study

References

• Morris ME, Iansek R, Matyas TA, et al. The pathogenesis of gait hypokinesia in Parkinson’s disease. Brain. 1994;117(Pt 5):1169–1181.
   PubMed Web of Science ®Google Scholar
• Okuma Y. Practical approach to freezing of gait in Parkinson’s disease. Pract Neurol. 2014;14(4):222–230.
   PubMedGoogle Scholar
• Kerr GK, Worringham CJ, Cole CH, et al. Predictors of future falls in Parkinson disease. Neurology. 2010;75(2):116–124.
   PubMed Web of Science ®Google Scholar
• Okuma Y, Yanagisawa N. The clinical spectrum of freezing of gait in Parkinson’s disease. Mov Disord. 2008;23(Suppl 2):S426–S430.
   PubMedGoogle Scholar
• Nonnekes J, Snijders AH, Nutt JG, et al. Freezing of gait: a practical approach to management. Lancet Neurol. 2015;14(7):768–778.
   PubMed Web of Science ®Google Scholar
• Devos D, Defebvre L, Boedet R. Dopaminergic and non-dopaminergic pharmacological hypotheses for gait disorders in Parkinson’s disease. Fundam Clin Pharmacol. 2010;24(4):407–421.
   PubMed Web of Science ®Google Scholar
• Schiffmann SN, Vanderhaeghen JJ. Adenosine A2 receptors regulate the gene expression of striatopallidal and striatonigral neurons. J Neurosci. 1993;13(3):1080–1087.
   PubMed Web of Science ®Google Scholar
• Kalia LV, Brotchie JM, Fox SH. Novel nondopaminergic targets for motor features of Parkinson’s disease: review of recent trials. Mov Disord. 2013;28(2):131–144.
   PubMed Web of Science ®Google Scholar
• Henderson EJ, Lord SR, Brodie MA, et al. Rivastigmine for gait stability in patients with Parkinson’s disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15(3):249–258.
   PubMed Web of Science ®Google Scholar
• Saki M, Yamada K, Koshimura E, et al. In vitro pharmacological profile of the A2A receptor antagonist istradefylline. Naunyn Schmiedebergs Arch Pharmacol. 2013;386(11):963–972.
   PubMed Web of Science ®Google Scholar
• Rosin DL, Robeva A, Woodard RL, et al. Immunohistochemical localization of adenosine A2A receptors in the rat central nervous system. J Comp Neurol. 1998;401(2):163–186.
   PubMed Web of Science ®Google Scholar
• Mori A, LeWitt P, Jenner P. The story of Istradefylline – the first approved A2A antagonist for the treatment of Parkinson’s Disease. In: Morelli M, Simola N, Wardas J, editors. The adenosinergic system: a non-dopaminergic target in Parkinson’s disease. Switzerland: Springer International Publishing; 2015. p. 273–289.
   Google Scholar
• Fuxe K, Ferré S, Genedani S, et al. Adenosine receptor-dopamine receptor interactions in the basal ganglia and their relevance for brain function. Physiol Behav. 2007;92(1–2):210–217.
   PubMed Web of Science ®Google Scholar
• Aoyama S, Kase H, Borrelli E. Rescue of locomotor impairment in dopamine D2 receptor-deficient mice by an adenosine A2A receptor antagonist. J Neurosci. 2000;20(15):5848–5852.
   PubMed Web of Science ®Google Scholar
• Chen JF, Moratalla R, Impagnatiello F, et al. The role of the D2 dopamine receptor (D2R) in A2A adenosine receptor (A2AR)-mediated behavioral and cellular responses as revealed by A2A and D2 receptor knockout mice. Proc Natl Acad Sci USA. 2001;98(4):1970–1975.
   PubMed Web of Science ®Google Scholar
• Mizuno Y, Hasegawa K, Kondo T, et al. Clinical efficacy of istradefylline (KW-6002) in Parkinson’s disease: a randomized, controlled study. Mov Disord. 2010;25(10):1437–1443.
   PubMed Web of Science ®Google Scholar
• Mizuno Y, Kondo T., Japanese Istradefylline Study Group. Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson’s disease. Mov Disord. 2013;28(8):1138–1141.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Hubble JP, Truong DD, et al. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology. 2003;61(3):297–303.
   PubMed Web of Science ®Google Scholar
• Kondo T, Mizuno Y, Japanese Istradefylline Study Group. A long-term study of istradefylline safety and efficacy in patients with Parkinson disease. Clin Neuropharmacol. 2015;38(2):41–46.
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Guttman M, Tetrud JW, et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson’s disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol. 2008;63(3):295–302.
   PubMed Web of Science ®Google Scholar
• Kitagawa M, Houzen H, Tashiro K. Effects of caffeine on the freezing of gait in Parkinson’s disease. Mov Disord. 2007;22(5):710–712.
   PubMed Web of Science ®Google Scholar
• Matsuura K, Kajikawa H, Tabei KI, et al. The effectiveness of istradefylline for the treatment of gait deficits and sleepiness in patients with Parkinson’s disease. Neurosci Lett. 2018;662:158–161.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Miyamoto T, Miyamoto M, et al. Could istradefylline be a treatment option for postural abnormalities in mid-stage Parkinson’s disease? J Neurol Sci. 2018;385:131–133.
   PubMed Web of Science ®Google Scholar
• Mitoma H, Yoneyama M, Orimo S. 24-hour recording of parkinsonian gait using a portable gait rhythmogram. Intern Med. 2010;49(22):2401–2408.
   PubMed Web of Science ®Google Scholar
• Mori A, Shindou T. Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists. Neurology. 2003;61(11Suppl 6): S44–S48. Erratum in: Neurology. 2004;62(2):348.
   PubMedGoogle Scholar
• Hickey P, Stacy M. Adenosine A2A antagonists in Parkinson’s disease: what’s next? Curr Neurol Neurosci Rep. 2012;12(4):376–385.
   PubMed Web of Science ®Google Scholar
• Postuma RB, Anang J, Pelletier A, et al. Caffeine as symptomatic treatment for Parkinson disease (Café-PD): a randomized trial. Neurology. 2017;89(17):1795–1803.
   PubMed Web of Science ®Google Scholar
• Fredholm BB, Bättig K, Holmén J, et al. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev. 1999;51(1):83–133.
   PubMed Web of Science ®Google Scholar
• Ochi M, Koga K, Kurokawa M, et al. Systemic administration of adenosine A(2A) receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study. Neuroscience. 2000;100(1):53–62.
   PubMed Web of Science ®Google Scholar
• Mori A. Mode of action of adenosine A2A receptor antagonists as symptomatic treatment for Parkinson’s disease. In: Mori A, editor. International review of neurobiology. Adenosine receptors in neurology and psychiatry. Amsterdam, The Netherlands: Elsevier B.V.; 2014. p. 87–116.
   Google Scholar
• Black KJ, Koller JM, Campbell MC, et al. Quantification of indirect pathway inhibition by the adenosine A2a antagonist SYN115 in Parkinson disease. J Neurosci. 2010;30(48):16284–16292.
   PubMed Web of Science ®Google Scholar
• Pinna A, Pontis S, Borsini F, et al. Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson’s disease. Synapse. 2007;61(8):606–614.
   PubMed Web of Science ®Google Scholar
• Kadowaki HT, Kobayashi M, Mori A, et al. Effects of the adenosine A2A antagonist istradefylline on cognitive performance in rats with a 6-OHDA lesion in prefrontal cortex. Psychopharmacology (Berl). 2013;230(3):345–352.
   PubMed Web of Science ®Google Scholar
• Takakusaki K. Neurophysiology of gait: from the spinal cord to the frontal lobe. Mov Disord. 2013;28(11):1483–1491.
   PubMed Web of Science ®Google Scholar
• Moore O, Peretz C, Giladi N. Freezing of gait affects quality of life of peoples with Parkinson’s disease beyond its relationships with mobility and gait. Mov Disord. 2007;22(15):2192–2195.
   PubMed Web of Science ®Google Scholar